eningiomas are common tumors of the central nervous system arising from cells of the meningeal coverings of the brain and spinal cord. Most meningiomas can be resected, often providing immediate relief from neurological deficits, seizures and other symptoms. Many studies have delineated the extent of resection as a powerful predictor of recurrence. [1] [2] [3] The clinical significance of tumor recurrence is high and the management of these patients poses specific challenges.
Conventional external beam radiation (EBR) and more recently conformal radiotherapy and radiosurgery are valuable additions to the therapeutic armamentarium. Radiosurgery is often recommended for non-resectable benign and non-benign tumor, i.e. in the cavernous sinus, sometimes after tumor progression has been confirmed by serial MR imaging. [4] [5] [6] [7] [8] [9] [10] A significant body of data supports adjuvant conventional EBR for patients with malignant meningiomas. [4] [11] [12] [13] Meningioma recurrence rates also strongly depend on intrinsic biological properties of the tumors as reflected in their histopathological appearance. [ [22] The 1979 WHO classification of central nervous system tumors recognized anaplastic/malignant meningiomas as a distinct tumor subtype. [23] Several studies have since established the existence of an intermediate category of meningiomas which carries a worse prognosis than the classic grade I tumor, but clearly displays a more favourable behavior than frankly malignant meningiomas. [18] [24] The 1993 WHO classification adopted the term atypical meningioma WHO grade II for such tumors. [24] Recurrence rates as high as 38-52% and 50-84% after 5 years have been reported for atypical and anaplastic/malignant meningiomas, respectively. [ [22] In 2000, a substantially revised WHO classification of meningiomas was published. [25] The literature provides no specific guidelines for postoperative radiotherapy or radiosurgery or MRI follow up protocols for grade I vs. atypical vs. anaplastic/malignant meningiomas. We have been impressed by an increasing proportion of tumors labelled as atypical/WHO grade II in recent years. At our institution, between 0-4 meningiomas (0-4.9%) were classified as atypical every year from 1994-1996, while from 1997-2003 numbers increased to 10-20 tumors (14.5-23.3% of all meningiomas). Similarly, in all recent large series the number of non-benign meningiomas approaches or exceeds 20% in contrast to earlier cohorts. [ 
METHODS

Patients
The impact of the revised 2000 WHO classification for the diagnosis of atypia and malignancy in meningiomas was investigated by reviewing the histological grading of 57 tumors operated in our department between February 1996 and September 1997. These tumors have already been reviewed in 1999 for an unrelated publication, allowing for a comparison of the 1999 and 2004 diagnoses. [27] All diagnoses were made at the German Reference Center for Brain Tumor Neuropathology (Deutsches HirntumorReferenzzentrum). Tumors with a papillary, rhabdoid, clear cell or chordoid differentiation were excluded. Relevant clinical information was obtained through a chart review. All patients gave informed consent before surgery to have their tumors included in a tumor bank for further studies. Approval of the ethics committee at the University of Bonn Medical Center was obtained for research using the tumor bank.
The WHO 1993 criteria were adhered to in 1999 with one exception. In addition and paralleling a worldwide debate among neuropathologists, a MIB1 index > 5% was deemed sufficient to allow for the diagnosis of atypia during the 1999 review. [24] [27] [28] [29] The WHO 1993 classification details contradictory views on brain invasion with some neuropathologists maintaining, that gross brain invasion even in the absence of histological malignancy may qualify a tumor for the designation malignant. [24] We considered brain invasion as a marker of malignancy in 1999. For the current review, the WHO 2000 classification was used. The WHO 2000 classification does not list brain invasion among the criteria for malignancy. The study was not blinded.
Survey of indications for postoperative radiotherapy/radiosurgery, and follow-up protocols
To assess the impact of meningioma grading (and any changes thereof) on the management policies for tumors of different histological grades, a questionnaire was sent to all German Neurosurgical units performing surgery for intracranial meningiomas (n=123) based on a current (9/2003) listing (www.dgnc.de) published by the German Neurosurgical Society (Deutsche Gesellschaft für Neurochirurgie). The chairmen were asked to detail the department's policies for postoperative radiotherapy and follow-up after surgery for WHO grade I, atypical WHO grade II, and anaplastic/malignant WHO grade III meningiomas.
Specifically, we asked if the centers would recommend conventional radiotherapy or conformal radiotherapy/radiosurgery after a complete (Simpson grades I-III) versus an incomplete resection of a WHO grade I, grade II, and grade III meningioma. Dates and intervals for MRI surveillance examinations could be ticked on the questionnaire as follows: postoperatively; first control after <3, 3, 6, and 12 months; follow-up intervals <6, 6, 12, and 24 months in the first 1-2 years after surgery; follow-up intervals <6, 6, 12, 24, and >24 months 2-5 years after surgery; follow-up intervals <6, 6, 12, 24, and >24 months 5-10 years after surgery; and follow-up intervals 6, 12, 24, and >24 months >10 years after surgery.
Sixty-four questionnaires were returned. 61/123 (49.6%) questionnaires could be used for further analysis. The WHO classification is used for meningioma grading in 59 institutions. A modified system is employed in one center. No information was available for one department. 
RESULTS
Comparison
Postoperative radiation therapy for meningiomas
The majority of the departments recommend radiotherapy/radiosurgery for patients with malignant tumors (after complete resection: n=40, after incomplete resection: n=54) and for residual atypical meningioma (n=40). A few centers (n=10) radiate at least some patients with completely resected atypical meningiomas. Half of the centers (n=23) consider some form of radiation therapy (mainly radiosurgery) for at least some patients with incompletely resected WHO grade I meningioma. Two units would not prescribe radiation therapy after surgery at all, even after incomplete resection of a malignant meningioma. Radiosurgery or conformal radiation is primarily used for incompletely resected tumor, conventional EBR is used most often for malignant meningiomas (table  2) . Some centers commented that they would reserve radiotherapy/radiosurgery for tumor recurrence or progression rather than using adjuvant radiation treatment. The format of the questionnaire did not specifically require the centers to report their policy for tumor recurrence. The WHO grade significantly influences recommendations for adjuvant radiation therapy in many centers. Table 3 details the consequences which would result from changing the histological grade of a meningioma e.g. by using a different grading system. Nine of 56 centers recommend conventional radiotherapy or conformal radiotherapy/radiosurgery after complete removal of a WHO grade II but not a WHO grade I tumor. Eighteen of 58 units radiate incompletely resected atypical but not benign meningiomas. More than half of the departments will use different radiation therapy algorithms for WHO grade III meningiomas when compared to WHO grade II meningiomas. Most commonly, EBR (after complete resection: 20, after incomplete resection: 16) or radiosurgery/conformal radiotherapy (after complete resection: 16, after incomplete resection: 9) is administered for grade III but not grade II meningiomas. 
Follow-up after meningioma resection
In the majority of the centers meningioma patients are followed for >10 years after surgery. However, 3-6 centers (depending on tumor grade and degree of resection) routinely order follow-up MRIs only for 1 year. Between 15/59 (after complete resection of a benign or atypical meningioma) and 24-25/59 centers (for incompletely resected tumors) use early postoperative MRI scanning to verify the presumed degree of resection (table 4) . F-up intervals n-m yrs (years)/n months, follow-up intervals n-m years/months after the initial surgery. The table also includes the mean number ± standard deviation, and range of MRIs obtained for selected periods of time. Not all questionnaires could be evaluated for all tumor grades and complete vs. incomplete resection. Overall numbers decline with longer follow-up reflecting differences in follow-up durations between centers. Numbers include centers obtaining MRI scans at the indicated intervals only in specific situations. Due to rounding errors percentages may not always add up to 100%.
All departments scan their patients at least once in the first year after surgery, most commonly after 3 months (31/59 centers after complete resection of a benign tumor, 51/59 units after incomplete surgery for malignant meningioma). Intervals between control MR scans are prolonged with time. In general, incomplete resection and increasing tumor grade correlate with an earlier first control MRI, shorter follow-up intervals and hence a larger overall number of MRI scans performed for follow-up. The precise follow-up protocols differ quite significantly between centers. On face value, the same patient may be followed in one unit for 1 year with 1 MRI and in another for >10 years with >30 MRI scans. Results are presented in detail in table 4.
Twelve centers seem to believe in a surgical cure for WHO grade I rather than for WHO grade II/III tumors. Correspondingly, follow-up is longer for at least some atypical and malignant meningiomas. Other units (n=6) apparently feel, that because of the generally higher growth rates of non-benign meningiomas, these tumors will regrow earlier. Therefore, a shorter follow-up should suffice after surgery for atypical or anaplastic meningioma.
DISCUSSION
Histological grading for meningiomas
The WHO grading for meningiomas has undergone significant changes in recent years. This study was therefore primarily motivated by growing concerns regarding the validity of clinical decision making based on the histological grading of meningiomas. The data presented suggest that, in part, the diagnostic labels "WHO grade I, II, and III" meningioma have been applied to different tumors before versus after the introduction of the new WHO classification in 2000. Specifically, among 57 meningiomas reviewed for this paper, almost half of the meningiomas diagnosed as atypical in 1999 (7/15=47%) were re-classified as WHO grade I. The majority of anaplastic/malignant tumors were regraded as atypical (4/6=67%) using the current WHO criteria.
Of note, no longer using two specific criteria to diagnose atypia and malignancy, i.e. an increased MIB1 index and brain invasion, resulted in down-grading of as many as 3 atypical/WHO grade II and 4 anaplastic/WHO grade III meningiomas. Employing immunohistochemical proliferation markers, in particular the MIB1 index, as an adjunct to the diagnosis of atypia has been amply discussed in the neuropathological literature. [28] [29] However, none of these markers have been included in the WHO classification. Brain invasion has once been considered the hallmark of malignancy in meningiomas. [26] More recent studies suggest a different view. [22] The 2000 WHO classification does not list brain invasion among the criteria for malignancy. [25] The clinical outcome of our patients with non-benign tumors (table 1) Hence, incompletely resected tumors should be radiated at some point during the course of the disease, when the risks of repeat surgery seem to outweigh the possible complications of radiotherapy and radiosurgery. A dose-response relationship for EBR after surgery for malignant meningioma has been described in two independent studies. [4] [11] Many consider EBR standard therapy after resection of these tumors.
However, a significant number of centers employ more controversial radiation therapy algorithms. Ten centers recommend radiation therapy for at least some completely resected atypical meningiomas. Forty departments feel that residual atypical tumor should be radiated. 25 units would prescribe radiotherapy or radiosurgery for incompletely resected atypical but not benign tumors. Such policies rely heavily on the assumption, that patients with an atypical tumor will do significantly worse than patients with benign meningiomas. The data provided in table 1 would not support this notion.
Two of 56 centers will not recommend radiotherapy or radiosurgery directly after incomplete removal of a malignant meningioma. Sixteen of 56 units replied that they do not suggest radiation therapy for completely resected malignant tumors. It might well be that some of these units reserve radiation treatment for documented tumor progression, which would not be properly reflected in our survey results
MRI follow up after meningioma surgery
To our knowledge there are no systematic studies analyzing the duration of follow-up and follow up intervals after meningioma surgery. The present paper allows to formulate recommendations based on averaged expert opinions: Obtaining a first control scan in the first year after surgery, commonly after 3-6 months, seems advisable. Thereafter, follow up intervals can probably be safely increased. Follow up intervals of 1 to >2 years depending on the time elapsed after the surgery would appear appropriate for benign tumors. Non-benign tumors may require shorter intervals, i.e. 6 months intervals in the first 2 (WHO grade II) and 5 years (WHO grade III) respectively. Incompletely resected tumors may need to be followed somewhat more closely. Tumors may require follow up for more than 10 years more or less regardless of tumor grade and completeness of resection.
The recommendations outlined are supported by clinical experience, and published growth rates and tumor doubling times. WHO grade II/III meningiomas may regrow within months after incomplete removal, and WHO grade I tumors can recur even after many years. We operated for a first recurrence of a malignant meningioma 5 months after the first surgery, and 19.75 years after the first surgery for a WHO grade I meningioma. A number of reports contain growth rates and tumor doubling times of incidental meningiomas and of recurrent tumors after subtotal or complete resection. [ [36] Assuming exponential growth, these data suggest control intervals of approximately 4-10 months for non-benign, and 16 months to 3 years for benign tumors, depending on the maximum acceptable size of the potential regrowth at the time of detection (1.5-2.9 cm). Longer control intervals would be safe after approximately 2.5 and 9 years of uneventful follow-up, respectively. Absolute growth rates of up to 18 mm/year and 20 cc/year for "benign", and 70 mm/year and 59 cc/year for atypical and malignant meningiomas have been reported which would theoretically require somewhat shorter control intervals initially (< 6 months for benign and < 2 months for non-benign meningiomas, respectively) (for calculations see appendix).
Finally, it seems important to recognize that following patients with MRI scanning has significant socio-economic implications. Based on the figures presented, average postoperative surveillance imaging for a completely resected meningioma costs € 2.300 for a WHO grade I, € 3.200 for a WHO grade II, and € 4.400 for a WHO grade III tumor (calculating with € 500 per MRI study) over 5 years.
Clinical implications
The data presented in this paper suggest that a significant number of atypical and anaplastic/malignant meningiomas are graded differently, when using the current WHO classification rather than criteria employed previously. Therefore, published and local experience with these tumors may be seriously flawed by the use of diagnostic labels characterizing different tumors over time. On the other hand, our survey clearly documents the critical role of the histological grade of a meningioma in clinical practice. In part, classification issues may actually explain the quite variable policies reported by the Neurosurgical units participating in our survey.
The outcome data reported in this paper could be cautiously interpreted to support more stringent criteria for atypia and malignancy in meningiomas. We would like to conclude that further correlative studies combining detailed treatment and outcome data with a standardized histopathological analysis (i.e. using the WHO 2000 criteria) are warranted. The histological grades as defined in the WHO 2000 classification rather than individual parameters have not been analyzed as prognostic parameters. [3] [20] [22] In the meantime, a careful reading of the neuropathological report beyond the final grading diagnosis is recommended, and averaged expert opinions with respect to radiotherapy and follow-up duration/intervals after surgery for meningiomas of different histological grade can be found in this paper. 
